[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Kane SV, Karpate AA, Bal M, Juvekar SL, Pai PS: Chemotherapy-induced neuronal maturation in sinonasal teratocarcinosarcoma--a unique observation. Head Neck Pathol; 2009 Mar;3(1):31-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced neuronal maturation in sinonasal teratocarcinosarcoma--a unique observation.
  • We report the first case of a SNTCS in 23 year old male treated with neo-adjuvant chemotherapy followed by cranio-facial resection.
  • On imaging, a bone destroying lesion of left paranasal sinuses and nasal cavity was identified.
  • The diagnosis of SNTCS could be offered only on the third biopsy which showed heterogeneous admixture of primitive neuroectodermal, epithelial and mesenchymal elements.
  • Tumor was excised after 4 cycles of neo-adjuvant chemotherapy.
  • The undifferentiated neuroectodermal cells were completely absent in the post chemotherapy specimen.
  • This case throws light on the morphologic evidence of chemotherapy induced maturation in the neuroectodermal component within SNTCS, an event hitherto not reported in the literature in case of SNTCS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / pathology. Cell Differentiation / drug effects. Neurons / pathology. Nose Neoplasms / pathology. Teratocarcinoma / pathology
  • [MeSH-minor] Biomarkers, Tumor. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Humans. Immunohistochemistry. Male. Neoadjuvant Therapy. Neoplasm Staging. Otorhinolaryngologic Surgical Procedures. Radiotherapy. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1988;45(3):148-52 [3368191.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Mar;112(3):496-500 [7870460.001]
  • [Cites] Hum Pathol. 1998 Jul;29(7):718-22 [9670829.001]
  • [Cites] Ann Diagn Pathol. 2006 Dec;10(6):339-42 [17126251.001]
  • [Cites] Ann Diagn Pathol. 2008 Dec;12(6):415-25 [18995206.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2002 Feb 1;62(2):159-64 [11788149.001]
  • [Cites] Pathology. 1983 Oct;15(4):413-9 [6674870.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):687-91 [15390296.001]
  • [Cites] Cancer. 1968 Apr;21(4):714-21 [5651269.001]
  • [Cites] Cancer. 1976 Aug;38(2):818-23 [974998.001]
  • [Cites] J Surg Oncol. 1977;9(1):21-8 [839794.001]
  • [Cites] Cancer. 1984 May 15;53(10):2140-54 [6322958.001]
  • [Cites] Pathol Int. 2001 Dec;51(12):942-7 [11844067.001]
  • (PMID = 20596986.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2807528
  • [Keywords] NOTNLM ; Neo-adjuvant chemotherapy / Neuronal maturation / Sinonasal tumours / Teratocarcinosarcoma
  •  go-up   go-down


2. Sugie T, Takeuchi E, Kunishima F, Yotsumoto F, Kono Y: A case of ductal carcinoma with squamous differentiation in malignant phyllodes tumor. Breast Cancer; 2007;14(3):327-32
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinoma derived from the lining epithelial cells in malignant phyllodes tumor is a rare neoplasm of the breast and belongs to the category of carcinosarcoma.
  • A pathological diagnosis of ductal carcinoma with squamous differentiation was made by fine needle aspiration and a core needle biopsy.
  • She underwent neoadjuvant chemotherapy followed by a modified radical mastectomy with a skin flap.
  • She experienced lung and facial bone metastases, microscopic features of which were consistent with the sarcomatous component of the original breast carcinosarcoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Neoplasms, Multiple Primary / diagnosis. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690514.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Roddie P, Collie D, Johnson P: Myelomatous involvement of the dura mater: a rare complication of multiple myeloma. J Clin Pathol; 2000 May;53(5):398-9
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient presented with blurring of vision in the right visual field and left sided facial numbness.
  • The infiltration of the dura mater is likely to have arisen by spread from contiguous bone lesions, contrasting with the pattern of spread seen in myelomatous involvement of the leptomeninges, which probably occurs through haematogenous seeding of the meninges.
  • Leptomeningeal involvement is associated with a very poor prognosis; however, this patient had a favourable response to combined chemotherapy and cranial radiotherapy, suggesting that myelomatous involvement of the dura mater should be considered as a distinct complication of myeloma.
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Prognosis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10889825.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Other-IDs] NLM/ PMC1731199
  •  go-up   go-down


Advertisement
4. Qin ZK, Yang GW, Zhou FJ, Han H, Liu ZW, Zhou NN, Wu ZG: [Short-term efficacy of combined chemotherapy of gemcitabine and cisplatin on advanced hormone refractory prostate cancer]. Ai Zheng; 2004 Dec;23(12):1700-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Short-term efficacy of combined chemotherapy of gemcitabine and cisplatin on advanced hormone refractory prostate cancer].
  • BACKGROUND & OBJECTIVE: Effective treatment for hormone refractory prostate cancer was required.
  • This study was to evaluate efficacy of combined chemotherapy of gemcitabine and cisplatin on hormone refractory prostate cancer, and its toxicities.
  • METHODS: Fifteen patients with advanced hormone refractory prostate cancer,who received castration and antiandrogen medicines,were conformed multiple bone metastatic carcinomas by emission computed tomography (ECT).
  • Before chemotherapy, 12 patients suffered from pain of bone metastasis with 4 cases of grade I, 5 cases of grade II, and 3 cases of grade III.
  • After chemotherapy, 9 patients released from pain,only 2 suffered from pain of grade I, 1 suffered from pain of grade II.
  • The maximal diameter of multiple intracranial metastatic lesions was reduced from 3.0 to 0.5 cm, and the symptoms of facial paralysis vanished.
  • Of 15 patients, 2 died of the disease,the median survival time was 14.7 months.
  • Mean time of pain remission was 13.6 months, and the stable period of PSA value descent was 12.3 months.
  • Toxicities of chemotherapy were tolerable, including nausea/vomiting,leukopenia,decreased hemoglobin,and thrombo- cytopenia.
  • CONCLUSIONS: Combined chemotherapy of gemcitabine and cisplatin is effective in treating advanced hormone refractory prostate cancer with tolerable toxicities, and could be considered as an adjuvant therapy for advanced hormone refractory prostate cancer.
  • [MeSH-major] Androgen Antagonists / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Castration. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Follow-Up Studies. Humans. Infusions, Intravenous. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Ribonucleotide Reductases / antagonists & inhibitors. Survival Rate


5. Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, Hogendoorn PC, Marreaud S, Van Glabbeke M, Blay JY: Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer; 2008 Nov;44(16):2433-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.
  • RATIONALE: Angiosarcomas of soft tissue represent a heterogenous group of rare sarcomas with specific clinical behaviour and risk factors.
  • METHOD: Clinical data from patients with angiosarcomas of soft tissue treated with single agent paclitaxel were collected from the centres of the soft tissue and bone sarcoma group of EORTC, using a standardised data collection form.
  • Primary angiosarcomas were located in scalp and face in 8 patients (25%) and at other primary sites in 24 patients (75%).
  • Thirteen (40%) patients had been pretreated with doxorubicin-based first-line-chemotherapy and three of them (9%) had also received second-line chemotherapy with ifosfamide.
  • Eleven (34%) patients had been irradiated before as treatment for angiosarcoma.
  • In 8 (25%) patients, the angiosarcoma occurred at sites of prior radiation therapy for other malignancies.
  • The median time to progression was 7.6 months (range, 1-42) for the whole group.
  • For the face/scalp group it was 9.5 months, and for patients with angiosarcomas at other sites it was 7.0 months, respectively.
  • CONCLUSION: Paclitaxel was found to be an active agent in angiosarcoma of soft tissue in this retrospective analysis.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Hemangiosarcoma / drug therapy. Paclitaxel / therapeutic use. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Facial Neoplasms / drug therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Retrospective Studies. Scalp. Skin Neoplasms / drug therapy. Young Adult


6. Selesnick SH, Burt BM: Regional spread of nonneurogenic tumors to the skull base via the facial nerve. Otol Neurotol; 2003 Mar;24(2):326-33
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional spread of nonneurogenic tumors to the skull base via the facial nerve.
  • OBJECTIVE: This study examined the clinical and pathologic features of regional spread of nonneurogenic neoplastic disease to the intratemporal segments of the facial nerve.
  • PATIENTS: Six patients with neoplastic disease of nonneurogenic origin involving segments of the facial nerve within the temporal bone.
  • Five patients received adjuvant radiation, and two received adjuvant radiation and chemotherapy.
  • MAIN OUTCOME MEASURES: Histopathology, site of primary tumor, intratemporal location of regional spread along the facial nerve, degree of facial paralysis, and presence of residual disease.
  • In addition, one case of benign pleomorphic adenoma of the parotid gland that circumferentially involved an intratemporal segment of the facial nerve was reported.
  • Facial paralysis was present in five of six (83%) of cases.
  • Four patients had unresectable malignant disease, and two died despite multimodality therapy.
  • CONCLUSIONS: The facial nerve provides a route for the spread of neoplastic disease into the temporal bone, and perineural invasion is an important mechanism of invasion and motility of malignant disease.
  • Nonneurogenic intratemporal tumors of the facial nerve are a rare but significant cause of facial paralysis.
  • [MeSH-major] Carcinoma / pathology. Cranial Nerve Neoplasms / pathology. Facial Nerve / pathology. Parotid Neoplasms / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Child. Female. Gadolinium. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Radiopharmaceuticals. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12621352.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


7. Viswanatha B: Embryonal rhabdomyosarcoma of the temporal bone. Ear Nose Throat J; 2007 Apr;86(4):218, 220-2
Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryonal rhabdomyosarcoma of the temporal bone.
  • The most common soft-tissue sarcoma in infants and children is rhabdomyosarcoma.
  • The head and neck is the most common site of involvement; temporal bone involvement has been seen in about 7% of reported cases.
  • Multimodality therapy--surgery, multiagent chemotherapy, and radiotherapy-yields sufficiently good results.
  • The author reports a case of embryonal rhabdomyosarcoma of the temporal bone with cranial nerve palsies and extension into the parapharyngeal space in a 4-year-old boy.
  • Despite surgery and chemotherapy, the patient died of his disease within 3 months of presentation.
  • [MeSH-major] Ear Canal. Ear Neoplasms / diagnosis. Ear, Middle. Facial Paralysis / etiology. Mastoid. Ophthalmoplegia / etiology. Rhabdomyosarcoma, Embryonal / diagnosis. Skull Neoplasms / diagnosis. Temporal Bone
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Palliative Care. Pharyngeal Neoplasms / diagnosis. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17500393.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Zwerger S, Günther L, Pekrun A, Krause HR, Rustemeyer J: A strategy to avoid facial mutilation in orbital embryonal rhabdomyosarcoma. Oral Maxillofac Surg; 2010 Dec;14(4):233-7
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A strategy to avoid facial mutilation in orbital embryonal rhabdomyosarcoma.
  • We detail the case of an 8-year-old female with orbital RMS and discuss the therapeutic options.
  • Open biopsy led to the histological diagnosis.
  • Metastasis or infiltration of orbital bone was not observed.
  • Chemotherapy was carried out in accordance with the Cooperative Weichteilsarkom Studie (CWS) 2002 protocol.
  • Tumor regression was detected after the first course of chemotherapy; we decided to excise the residual tumor with preservation of the globe.
  • One year after treatment, RMS recurrence was not observed.
  • CONCLUSION: After interdisciplinary treatment, mutilation was avoided after exenteration of the orbit or radiation treatment to the growing facial skeleton.
  • [MeSH-major] Face / surgery. Orbital Neoplasms / surgery. Postoperative Complications / prevention & control. Rhabdomyosarcoma, Embryonal / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Female. Follow-Up Studies. Humans. Muscle Neoplasms / surgery. Neoadjuvant Therapy. Neoplasm Staging. Oculomotor Muscles / pathology. Oculomotor Muscles / surgery. Ophthalmologic Surgical Procedures / methods. Remission Induction

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Control. 2004 Sep-Oct;11(5):328-33 [15377992.001]
  • [Cites] Ophthalmology. 2001 Dec;108(12):2284-92 [11733272.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1904-22 [8448756.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Dec;11(12):2057-65 [4066437.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):104-9 [10918231.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Feb 1;31(3):675-6; discussion 681 [7852136.001]
  • [Cites] J AAPOS. 2000 Oct;4(5):318-20 [11040485.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Surv Ophthalmol. 2003 Jan-Feb;48(1):39-57 [12559326.001]
  • [Cites] Trans Am Ophthalmol Soc. 1965;63:223-55 [5859786.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3706-19 [10577842.001]
  • [Cites] Neuroimaging Clin N Am. 1996 Feb;6(1):123-42 [8919138.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Apr;126(4):468-72 [10772299.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5108-12 [8221646.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3844-51 [16921036.001]
  • [Cites] Radiol Clin North Am. 1998 Nov;36(6):1215-27, xii [9884698.001]
  • [Cites] Int J Oral Maxillofac Surg. 2009 Mar;38(3):256-60 [19153030.001]
  • [Cites] AMA Arch Ophthalmol. 1959 Aug;62(2):203-10 [13669797.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):197-204 [11134213.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5340-8 [10498887.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4742-9 [16651427.001]
  • (PMID = 20143115.001).
  • [ISSN] 1865-1569
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Chee G, Mok P, Sim R: Squamous cell carcinoma of the temporal bone: diagnosis, treatment and prognosis. Singapore Med J; 2000 Sep;41(9):441-6, 451
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the temporal bone: diagnosis, treatment and prognosis.
  • The development of an accepted staging system has not been forthcoming and this has inhibited the formation of an evidence-based therapeutic protocol.
  • Five patients had facial palsy which was a poor prognostic sign.
  • With combination treatment involving surgery, radiotherapy and chemotherapy, disease free survival achieved was 69% (9 of 13) over a mean follow-up period of 24.7 months.
  • One patient absconded treatment.
  • Patients with facial nerve involvement had a significantly poorer outcome (p = 0.035).
  • [MeSH-major] Carcinoma, Squamous Cell. Skull Neoplasms. Temporal Bone / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11193117.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


10. Yoshida N, Kanekura T, Hashiguchi T, Nagayama T, Hamada H, Kanzaki T: Primary squamous cell carcinoma of the frontal sinus. J Dermatol; 2006 Dec;33(12):855-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging (MRI) revealed invasion of the anterior wall of the ethmoid sinus, the frontal bone, and possibly the meninx by a frontal sinus carcinoma.
  • Despite right fronto craniotomy with en bloc resection followed by two courses of radiation therapy and chemotherapy with 5-fluorouracil and nedaplatin or TS-1 he died of disease-related causes 20 months later.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Frontal Sinus / pathology. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Ethmoid Sinus / pathology. Facial Neoplasms / diagnosis. Fatal Outcome. Frontal Bone / pathology. Humans. Male. Neoplasm Invasiveness. Skull Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17169089.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 10
  •  go-up   go-down


11. Yin M, Ishikawa K, Honda K, Arakawa T, Harabuchi Y, Nagabashi T, Fukuda S, Taira A, Himi T, Nakamura N, Tanaka K, Ichinohe M, Shinkawa H, Nakada Y, Sato H, Shiga K, Kobayashi T, Watanabe T, Aoyagi M, Ogawa H, Omori K: Analysis of 95 cases of squamous cell carcinoma of the external and middle ear. Auris Nasus Larynx; 2006 Sep;33(3):251-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ninety five cases of patients from 10 institutions were reviewed on their age and sex distribution, initial complaints, stages, tumor locations, treatments, and outcomes.
  • SCC in stages I and II was susceptible to each therapeutic strategy with a 5-year survival of 100%.
  • Operation combined with radiotherapy and/or chemotherapy was the major treatment for stages III and IV SCC, while radiotherapy and chemotherapy were applied mainly for those who had been considered inappropriate for operation.
  • The overall survival was 67.2% for stage III and 29.5% for stage IV, and operation with pathologically tumor free margin could improve the survival to 72.7% when combined with radio- and chemotherapy.
  • Early diagnosis and treatment were important because SCC in the earlier stage is susceptible to be cured.
  • For tumors of advanced stage, operation should be performed with pathologically tumor free margin, and operation combined with radiotherapy and chemotherapy could improve the survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Earache. Facial Paralysis. Female. Hearing Loss. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Prognosis. Retrospective Studies. Survival Analysis. Temporal Bone / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16431060.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


12. Velche-Haag B, Dehesdin D, Proust F, Marie JP, Andrieu-Guitrancourt J, Laquerriere A: [Ewing's sarcoma of the head and neck: a case report]. Ann Otolaryngol Chir Cervicofac; 2002 Dec;119(6):363-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient complained of facial pain, anosmia and visual defect.
  • Diagnosis was established at microscopic examination with histoimmunochemistry and molecular biology.
  • Treatment combined chemotherapy and surgical resection with skull base reconstruction and post-operative ratio and chemotherapy.
  • [MeSH-major] Bone Neoplasms / therapy. Ethmoid Sinus / surgery. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adult. Antibodies, Neoplasm / immunology. Antigens, CD / immunology. Cell Adhesion Molecules / immunology. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12527847.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules
  •  go-up   go-down


13. Hesseling P, Molyneux E, Kamiza S, Israels T, Broadhead R: Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate. Ann Trop Paediatr; 2009 Mar;29(1):29-34
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate.
  • BACKGROUND: Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in equatorial Africa and there is a need for affordable, effective treatment.
  • AIM: To record the morbidity of treatment and event-free survival after 1 year using relatively high doses of cyclophosphamide at short intervals combined with intrathecal methotrexate.
  • The initial diagnosis was made clinically and confirmed by fine-needle aspiration in 73%.
  • Abdominal ultrasound, bone marrow aspirate and CSF analysis were undertaken routinely.
  • Chemotherapy consisted of cyclophosphamide, 40 mg/kg on day 1 and 60 mg/kg on days 8, 18 and 28.
  • Allopurinol was commenced before chemotherapy, and a high urinary output was maintained to prevent tumour lysis.
  • An equal number (70%) presented with abdominal and facial disease, and 15% with paraplegia.
  • Two patients died during treatment, three had chemotherapy-resistant disease and 35 (88%) achieved complete clinical remission by day 28.
  • Sixteen required antibiotic treatment for presumed infection and nine received a blood transfusion.
  • CONCLUSION: This short, inexpensive treatment schedule (<50 US$) cured almost 50% of eBL patients in a setting of very limited resources.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Methotrexate / administration & dosage. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222931.001).
  • [ISSN] 1465-3281
  • [Journal-full-title] Annals of tropical paediatrics
  • [ISO-abbreviation] Ann Trop Paediatr
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


14. Wei F, Liu X, Liu Z, Jiang L, Dang G, Ma Q, Dang L: Interferon alfa-2b for recurrent and metastatic giant cell tumor of the spine: report of two cases. Spine (Phila Pa 1976); 2010 Nov 15;35(24):E1418-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To demonstrate that interferon alfa-2b is a therapeutic option for obtaining long-term control of recurrent and metastatic giant cell tumor of spine.
  • SUMMARY OF BACKGROUND DATA: Interferon alfa served as angiogenesis inhibitor and has been successfully used to treat giant cell tumor of long bones and facial bones.
  • Up to date, no report is found with regard to the use of interferon as a stand-alone treatment for unresectable, recurrent, and metastatic giant cell tumor originated from the spine.
  • METHODS: A 29-year-old woman with C1 and C2 giant cell tumor was treated by radiotherapy, intralesional curet, and chemotherapy orderly.
  • Tumor recurred second time and caused severe spinal cord compression.
  • Six months later, a giant metastatic lesion was found in sacrococcygeal region, which was excised and proved to be giant cell tumor of bone.
  • CONCLUSION: Interferon therapy may be an effective and safe treatment for spine giant cell tumor recurrence and metastasis in soft tissue.
  • The effectiveness may be time and dosage dependent.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Giant Cell Tumor of Bone / drug therapy. Interferon-alpha / therapeutic use. Neoplasm Recurrence, Local. Spinal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Biopsy. Female. Humans. Magnetic Resonance Imaging. Male. Recombinant Proteins. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21030898.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


15. Kawano K, Ono K, Yada N, Takahashi Y, Kashima K, Yokoyama S, Yanagisawa S: Malignant calcifying epithelial odontogenic tumor of the mandible: report of a case with pulmonary metastasis showing remarkable response to platinum derivatives. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jul;104(1):76-81
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a case of CEOT of the mandible, which underwent malignant transformation and developed metastatic tumors of the lung after repeated local recurrence.
  • Chemotherapy was carried out against the pulmonary metastatic lesions, which showed a drastic response after 3 courses of intravenous administration of cisplatin (CDDP).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Lung Neoplasms / drug therapy. Mandibular Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Odontogenic Cyst, Calcifying / drug therapy
  • [MeSH-minor] Bone Transplantation. Humans. Male. Mandible / radiography. Mandible / surgery. Middle Aged. Organoplatinum Compounds / therapeutic use

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577547.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Sakamoto E, Yamane T, Nakane T, Takeoka Y, Hirose A, Hagihara K, Nakamae H, Ohta K, Hirayama M, Ikura Y, Ohsawa M, Sawada T, Kitoh T, Hino M: [Temporary effective treatment with L-asparaginase for a patient with refractory nasal NK/T-cell lymphoma]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1993-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Temporary effective treatment with L-asparaginase for a patient with refractory nasal NK/T-cell lymphoma].
  • A 48-year-old man was referred to Sakai Municipal Hospital with nasal discharge and right facial swelling.
  • He was admitted to our hospital and received CHOP therapy, resulting in progressive disease.
  • Irradiation therapy combined with DeVIC chemotherapy also could not shrink his lymphoma.
  • On the day before a third course of L-Asp, he again developed a lowgrade fever.
  • Post-mortem examinations revealed hemophagocytosis in the bone marrow and liver, and infiltration of lymphoma cells into multiple organs including left lower lung, liver, spleen and kidneys.
  • Although L-Asp was effective against nasal NK/T-cell lymphoma resistant to combination chemotherapy and irradiation therapy, the effectiveness of the single agent with L-Asp was only transient.
  • L-Asp based regimen should be used as first-line therapy if asparagine synthetase protein expression is low using an immunohistochemical method.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Asparaginase / therapeutic use. Lymphoma, T-Cell / drug therapy. Nose Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Drug Administration Schedule. Fatal Outcome. Humans. Kidney Neoplasms / pathology. Liver Neoplasms / pathology. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282743.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


17. Ogino S, Iino Y, Nakamoto Y, Murakami Y, Toriyama M: [Histopathological study of the temporal bones in patients with primary carcinomas of the ear]. Nihon Jibiinkoka Gakkai Kaiho; 2000 Oct;103(10):1141-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common symptoms of patients with carcinomas of the middle ear or mastoid are otorrhea, facial paralysis, and hearing loss, including a sensorineural element and vertigo.
  • Temporal bone sections from five patients (age: #39-73 years; 3 males and 2 females) who died from a primary carcinoma of the ear were studied histologically.
  • 1) localization of the tumor in the temporal bone, 2) pattern of tumor invasion in the inner ear, 3) pathological changes in the inner ear, including the cochlea, vestibule and semicircular canals.
  • Tumor cells were still present in the temporal bone sections of all the patients except one, even though the patients had received various treatments for the carcinoma, including radiation therapy, surgery and chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Ear Neoplasms / pathology. Ear, Inner / pathology. Temporal Bone / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11109823.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


18. Blank LE, Koedooder K, van der Grient HN, Wolffs NA, van de Kar M, Merks JH, Pieters BR, Saeed P, Baldeschi L, Freling NJ, Koning CC: Brachytherapy as part of the multidisciplinary treatment of childhood rhabdomyosarcomas of the orbit. Int J Radiat Oncol Biol Phys; 2010 Aug 1;77(5):1463-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brachytherapy as part of the multidisciplinary treatment of childhood rhabdomyosarcomas of the orbit.
  • Our specifically developed approach consists of applying brachytherapy to the tumor area using a mold.
  • METHODS AND MATERIALS: Thirteen patients were referred for brachytherapy if complete remission was not reached after chemotherapy (Group I) and 7 in case of relapse (Group II).
  • The dose to the clinical target volume was 40-50 Gy.
  • RESULTS: Three patients of Group I and 1 patient of Group II developed local recurrence and underwent exenteration.
  • During treatment, no serious side effects were observed.
  • The late complications encountered in this series were cataract in 2 patients, 1 of whom also developed mild retinopathy.
  • No facial asymmetries or bone growth anomalies were observed.
  • CONCLUSIONS: This entire procedure of brachytherapy with a mold offers a tailor-made treatment for orbital rhabdomyosarcomas with only few signs of late toxicity.
  • [MeSH-minor] Adolescent. Cataract / etiology. Child. Child, Preschool. Combined Modality Therapy / methods. Disease-Free Survival. Eye Enucleation. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Radiotherapy Dosage. Remission Induction / methods. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19864080.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Pitak-Arnnop P, Bellefqih S, Bertolus C, Chaine A, Dhanuthai K, Gruffaz F, Bertrand JC: Ewing's sarcoma of jaw bones in adult patients: 10-year experiences in a Paris university hospital. J Craniomaxillofac Surg; 2008 Dec;36(8):450-5
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Despite using aggressive treatment, patients with Ewing's sarcoma (ES) always show a high recurrence and a low survival rate.
  • PATIENTS AND METHODS: This case report identified the Ki-67 expression in jaw bone ES from 4 adult patients operated upon between 1996 and 2005 in Pitié-Salpêtrière University Hospital, Paris, France.
  • Two of 4 patients with 50% and 80% of Ki-67 positive tumour cells had local relapse at 5 years and 8 months after treatments, respectively.
  • Furthermore, the patient with 80% Ki-67 expression exhibited resistance to chemotherapy and died a year after resection.
  • CONCLUSION: Ki-67 expression is likely to be associated with tumour recurrence and poor prognosis in jaw bone ES in adult patients.
  • This marker probably helps surgeons to plan and employ appropriate treatment and/or surveillance for each patient; however, the number of cases in this series is very limited.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Jaw Neoplasms / pathology. Ki-67 Antigen / metabolism. Neoplasm Recurrence, Local / metabolism. Sarcoma, Ewing / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18674924.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


20. Danesi G, Panizza B, Mazzoni A, Calabrese V: Anterior approaches in juvenile nasopharyngeal angiofibromas with intracranial extension. Otolaryngol Head Neck Surg; 2000 Feb;122(2):277-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although surgery is regarded as the mainstay of treatment for juvenile nasopharyngeal angiofibromas (JNAs), ancillary treatment modalities such as radiotherapy and on rare occasions chemotherapy are still recommended by many for intracranial extension with apparent radiologic involvement of the cavernous sinus and internal carotid artery.
  • Total removal was achieved in 11 of the 14 cases with a single-stage procedure.
  • In the last 2 cases we preferred a midface degloving technique to avoid facial scarring and because this approach allows a widening of the surgical field if needed by the performance of bilateral maxillary free bone flaps.
  • On the rare occasion that a lateral approach, with its attendant permanent conductive hearing loss, is found to be necessary for total tumor removal, this can be done as a staged procedure.
  • [MeSH-minor] Adolescent. Adult. Carotid Artery, Internal / pathology. Cavernous Sinus / pathology. Child. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10652407.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Mücke T, Haarmann S, Wolff KD, Hölzle F: Bisphosphonate related osteonecrosis of the jaws treated by surgical resection and immediate osseous microvascular reconstruction. J Craniomaxillofac Surg; 2009 Jul;37(5):291-7
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: This report presents two patients who received treatment with bisphosphonates (BPs) and who subsequently developed BP related osteonecrosis of the jaws (BRONJ).
  • The treatment of advanced cases with BRONJ is an area of investigation.
  • RESULTS: Both patients underwent successful resection of the affected bone with immediate reconstruction by microvascular flap transfer.
  • CONCLUSIONS: Radical resection followed by microvascular composite flap reconstruction is reliable in the management of patients with advanced BRONJ and can be considered as the fourth therapeutic stage.
  • [MeSH-major] Bone Density Conservation Agents / adverse effects. Diphosphonates / adverse effects. Mandibular Diseases / chemically induced. Osteonecrosis / chemically induced. Reconstructive Surgical Procedures / methods
  • [MeSH-minor] Bone Transplantation / methods. Female. Humans. Middle Aged. Neoplasm Metastasis / drug therapy. Oral Surgical Procedures / methods. Severity of Illness Index. Surgical Flaps. Treatment Outcome

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179088.001).
  • [ISSN] 1878-4119
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  •  go-up   go-down


22. Farias TP, Dias FL, Lima RA, Kligerman J, de Sá GM, Barbosa MM, Gonçalves FB Jr: Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg; 2003 Jul;129(7):794-9
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Nasopharyngeal cancer (NPC) is a distinct form of cancer of the upper respiratory or digestive tract in which the epidemiologic features, origin, histopathologic types, treatment, and prognosis are different from those associated with other malignant neoplasms of this anatomical area.
  • Recent publications have demonstrated the advantage of aggressive multimodality treatment for advanced NPC.
  • OBJECTIVES: To evaluate the results of standardized treatment of NPC during 11 years and to identify pertinent factors for clinical outcome.
  • METHODS: Between January 1, 1989, and December 31, 2000, 173 patients with newly diagnosed NPC were treated at Instituto Nacional de Cancer.
  • Documented data of the initial presenting symptoms, head and neck examination, radiotherapy protocols, chemotherapy regimens, and surgical technique were analyzed.
  • To determine important prognostic factors, we correlated survival rates with age, clinical stage, tumor extent, histopathological type, and therapeutic approach.
  • Gross extension of the primary tumor involving the facial bones and skull base was observed in 39.3% and 20.8%, respectively.
  • Just under 75% of patients were treated with radiotherapy (median dose, 6600 cGy), and 25.4% underwent concomitant chemoradiotherapy with adjuvant chemotherapy (cisplatin plus 5-fluorouracil) (median dose, 6800 cGy).
  • The disease-specific survival for the radiotherapy group was 22.5%, compared with 61.4% for the chemoradiotherapy plus adjuvant chemotherapy group (P =.004).
  • Factors associated with adverse outcomes were age older than 40 years at treatment (P =.001), advanced TNM stage (P =.002), skull base invasion (P =.004), and facial bone invasion (P<.001).
  • CONCLUSIONS: Compared with radiotherapy alone, concomitant chemoradiotherapy with adjuvant chemotherapy improved the treatment outcome of patients with NPC treated in our institution.
  • [MeSH-major] Nasopharyngeal Neoplasms / mortality. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Brachytherapy. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12874084.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Park KA, Oh SY: Nasopharyngeal carcinoma presenting with rapidly progressive severe binocular optic neuropathy and periocular pain in a young man. J Neuroophthalmol; 2010 Jun;30(2):150-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For a presumptive diagnosis of retrobulbar optic neuritis, he was treated with intravenous corticosteroids, and vision improved transiently.
  • Nasopharyngoscopy disclosed a soft tissue lesion filling the apex of the nasopharynx and the posterior portion of the ethmoid sinus with associated sinusitis.
  • [MeSH-major] Carcinoma / complications. Carcinoma / pathology. Facial Pain / etiology. Nasopharyngeal Neoplasms / complications. Nasopharyngeal Neoplasms / pathology. Optic Nerve Diseases / etiology
  • [MeSH-minor] Adult. Blindness / etiology. Diagnosis, Differential. Diagnostic Errors / prevention & control. Disease Progression. Drug Therapy. Dura Mater / pathology. Ethmoid Sinus / pathology. Eye / physiopathology. Humans. Magnetic Resonance Imaging. Male. Nasopharynx / pathology. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Optic Nerve / pathology. Optic Nerve / physiopathology. Sella Turcica / pathology. Skull Base Neoplasms / secondary. Sphenoid Bone / pathology. Time Factors. Vision, Low / etiology

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414132.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement